A Complete Framework for Developing Investment Ideas and Underwriting Any Opportunity

A Step-by-Step Guide with Real-World Case Study: From Building Financial Models to Writing Investment Memos

Note: All numbers in this post are based on an actual 2023 investment analysis and are used for educational purposes to demonstrate analytical frameworks. This case study is presented for teaching purposes only and does not constitute investment advice.

Introduction: The Art of Bottom-Up Analysis

When I evaluate investment opportunities, I follow a systematic, process-oriented approach that focuses relentlessly on downside protection. My philosophy boils down to four core principles that guide every investment decision I make.

First, I focus on process-oriented risks rather than outcome-oriented predictions. This means asking what operational or structural factors could impair the investment, rather than trying to forecast whether management will hit their revenue targets. Second, I focus exclusively on downside scenarios rather than upside projections. The question isn’t how much I can make, but how much I can lose and what protects me from losing it. Third, I constantly ask myself “what am I missing?” and challenge every assumption I’ve made. Fourth, I’ve learned that everything boils down to a few factors—typically two or three variables that truly matter. The art is stripping away the noise to find those core drivers.

Today, I’ll walk you through exactly how I apply this framework using a real-world example: Mallinckrodt plc analyzed in May 2023, several months before the company’s second bankruptcy filing in August. This case perfectly illustrates how disciplined capital structure analysis, combined with an obsessive focus on downside protection, can identify compelling risk-adjusted opportunities even in situations that appear complex or distressed on the surface.

The Mallinckrodt Situation: Brief Context

In mid-2023, Mallinckrodt was a global pharmaceutical company that had emerged from its first bankruptcy in June 2022. The company operated through two segments: Specialty Brands (generating approximately 76% of net sales) and Specialty Generics (24% of net sales). Despite completing a reorganization that reduced debt by approximately $1.3 billion, the company faced significant challenges including ongoing litigation uncertainties, allegations of fraudulent financial reporting by activist investor Buxton Helmsley, and near-term debt maturities in 2025.

The company’s market valuation reflected deep distress. While net sales were approximately $1.9 billion with historical EBITDA margins of 35-40%, the senior secured bank debt traded at only 66-68% of par value. The equity market capitalization of approximately $1.6 billion suggested significant skepticism about the company’s ability to service its debt obligations. Most tellingly, Mallinckrodt’s enterprise value implied a 4.24x EV/EBITDA multiple compared to peer averages of approximately 5.0x—a discount that seemed to price in substantial execution risk or worse.

For capital structure investors in May 2023, this created a specific question: where in the capital structure offered the best risk-adjusted returns given the upcoming 2025 maturity wall and operational uncertainties?

The Investment Analysis Exercise

Before diving into the analysis, I want to share the exact analytical exercise that this situation presented. This is the type of work that creates edge in distressed credit investing:

Task 1 - Create the Corporate Model: Review the publicly disclosed information on the company and create a working three-statement model as well as supporting analyses including, but not limited to, valuation, scenario and sensitivity analyses, and returns analysis. Visit

https://ir.mallinckrodt.com/

for investor materials. Make all tabs link so you can explore key assumptions and trace how they flow through the analysis.

Task 2 - Outline Your Recommendation in a Long-Form Investment Memo: As an investor, if given the option to invest in the debt or equity of the company, describe which tranche you would seek to invest in and why. Note that debt and equity securities do not need to be purchased at par—in fact, the distressed pricing is often where the opportunity exists.

This two-part exercise—building the detailed analytical foundation, then synthesizing it into a clear investment recommendation—mirrors the actual work process of professional distressed investors. Let me walk you through exactly how I approached this.

Step 1: Building the Corporate Model and Understanding Structure

Before analyzing any opportunity, I start with the foundational work that most investors rush through: building a complete three-statement financial model and mapping the corporate structure. This isn’t about creating a 50-tab spreadsheet with five years of monthly projections—that’s typically wasted effort. Rather, it’s about understanding where cash is generated, where debt sits, and how entities relate to one another within the corporate structure.

For Mallinckrodt, I began by constructing a corporate structure chart that revealed the specific legal entities and where each debt instrument sat in the structure. At the top sat Mallinckrodt Plc, the publicly traded parent company. Below that were two key financing subsidiaries: Mallinckrodt International Finance SA (which issued the term loans) and Ludlow LLC/MA. Further down the structure sat Mallinckrodt International Finance SA/Mallinckrodt CB LLC and MEH (Mallinckrodt Enterprises Holdings), which were the operating entity holding companies.

The debt structure showed that the 2017 and 2018 Replacement Term Loans were issued by Mallinckrodt International Finance SA with guarantees from substantially all subsidiaries. The First Lien Bonds (both the April 2025 and December 2028 tranches) were issued at different levels of the structure but shared pari passu first lien status with the term loans on substantially all assets. The Second Lien Bonds sat junior to all first lien debt with second-priority claims on the same collateral package. This structure mapping immediately revealed that all first lien debt—whether term loans or bonds—had equal priority claims on the operating assets of the business.

The three-statement model revealed several critical insights about the business fundamentals. Looking at the income statement, Mallinckrodt generated net sales of $1,919 million in 2022 with cost of goods sold of $1,304 million, producing gross profit of $615 million (32% gross margin). After SG&A of $534 million and R&D costs of $130 million, the company generated negative operating profit of $49 million. However, adding back $718 million in depreciation and amortization produced EBITDA of $669 million, representing a 35% EBITDA margin. This distinction between operating profit and EBITDA was crucial—the business generated substantial cash flow despite accounting losses driven by heavy amortization of intangible assets.

The balance sheet as of year-end 2022 showed total assets of $5.5 billion, consisting of $410 million in cash, $405 million in accounts receivable, $948 million in inventory, $458 million in property, plant and equipment, and $2,843 million in intangible assets. On the liability side, total debt stood at $3,028 million, with the detailed breakdown across the various tranches providing the foundation for the capital structure analysis. The cash flow statement revealed levered free cash flow of $703 million in 2022, with capital expenditures of only $133 million, demonstrating the relatively low capital intensity of the pharmaceutical business model once you controlled for the litigation settlement payments.

Most importantly, I mapped exactly where in the corporate structure each debt instrument sat and which assets secured each claim. The 2017 Replacement Term Loan of $1,238 million and the 2018 Replacement Term Loan of $329 million were issued by Mallinckrodt International Finance SA with first-priority liens on substantially all assets of the issuers and guarantors, equal and ratable with liens securing the First Lien Bonds. The First Lien Bonds totaling $1,038 million ($449mm due April 2025 and $589mm due December 2028) shared the same security package. This meant the total first lien debt of $2,606 million all had pro rata claims on the collateral pool, representing 3.89x leverage against 2022 EBITDA of $669 million.

Step 2: Mapping the Complete Capital Structure

With the corporate structure understood, I then mapped out the complete capital structure to understand seniority, security, and recovery dynamics with precision. This step is absolutely critical because the relative positioning of different claims determines everything about recovery values in distress scenarios.

At the top of the capital structure sat the first lien secured debt totaling $2,606 million, consisting of the 2017 Replacement Term Loan ($1,238mm, LIBOR+525bps, maturing September 2027), the 2018 Replacement Term Loan ($329mm, LIBOR+525bps, maturing September 2027), the 10.00% First Lien Notes due April 2025 ($449mm), and the 11.50% First Lien Notes due December 2028 ($589mm). All of these instruments shared first-lien status on a pari passu basis with equal priority claims on substantially all assets. The term loans traded at 66-68% of par, while the bonds traded at varying discounts ranging from 75-81% of par.

Junior to the first lien debt sat the second lien secured debt totaling $590 million, including the 10.00% Second Lien Notes due April 2025 ($292mm) and the 11.50% Second Lien Notes due June 2029 ($298mm). These bonds had second-priority liens on the same collateral package that secured the first lien debt, meaning they could only recover from the collateral after first lien claims were fully satisfied. The second lien bonds traded at steep discounts of 48-58% of par, reflecting the market’s view that these securities faced material impairment risk in any distress scenario.

Below the secured debt sat unsecured claims, most significantly including the opioid settlement obligations that had been established in the first bankruptcy. The company also had general unsecured creditor claims including trade payables and other contractual obligations. At the bottom of the capital structure sat the common equity with a book value of $1,614 million but trading at a market capitalization of only $56 million, implying that the equity market assigned minimal value to the residual claims after debt service obligations.

The enterprise value math revealed the market’s distressed view of the situation. With $2,606 million of first lien debt marked at market (approximately $1,842 million market value given the 66-75% trading levels), $590 million of second lien debt marked at market (approximately $313 million given the 48-58% trading levels), equity at $56 million, and cash of $410 million, the implied enterprise value was only $1,801 million. This represented just 2.69x 2022 EBITDA of $669 million—dramatically below the peer average of approximately 5.0x and even below the company’s own historical trading multiples.

This capital structure mapping immediately revealed the key analytical insight: with total first lien debt of $2,606 million trading at distressed levels against a business generating $669 million of EBITDA, the critical question was whether asset values and cash flow generation could support full recovery for first lien holders, and if so, at what point in the capital structure the value break occurred.

Step 3: Identifying the Core Investment Thesis

Here’s where most analysts go wrong in distressed situations—they get lost in detailed financial models projecting Acthar Gel prescription trends five years out, or elaborate competitive analysis of the specialty generics market. Instead, I force myself to answer one question before doing any other work: what are the two or three factors that will determine this investment’s success or failure?

For the Mallinckrodt 2017 Replacement Term Loan opportunity trading at 66-68% of par in May 2023, the entire investment case boiled down to a simple thesis with an explicit catalyst.

The company faced $741 million of debt maturities in April 2025 (the First Lien and Second Lien bonds due that month) combined with a $200 million opioid settlement payment due mid-June 2023. With only $410 million of cash on hand and limited access to capital markets given the distressed trading levels, the company would almost certainly need to restructure or refinance its capital structure. This near-term catalyst—within 12-24 months—would force a crystallization event where value would be allocated across the capital structure based on legal priority and recovery analysis.

As a holder of the 2017 Replacement Term Loan, you sat at the top of the capital structure with first lien secured claims. In any restructuring or refinancing scenario, the term loan would either receive full par recovery (if the company could access capital to refinance), receive par plus a premium (if lenders demanded better terms to participate in a refinancing), or in a worst case liquidation scenario, recover based on collateral value. The key insight was that the business generated substantial EBITDA of $669 million and possessed valuable assets including intellectual property, manufacturing facilities, and working capital that provided multiple layers of downside protection.

The investment thesis was therefore: buy the term loan at 66-68% of par, capturing an immediate 32-34% discount to par. The upcoming maturity wall and opioid payment creates a near-term catalyst that will force either restructuring or refinancing within 12-24 months. In the base case where the company successfully restructures, the term loan recovers at or above par, generating 27-28% IRR and 2.1x MOIC. Even in downside scenarios involving significant asset impairment, the first lien position recovers 47-64% based on conservative liquidation values, limiting losses while still generating positive returns from the significant discount to par.

This is the power of simplification through rigorous analysis. The entire investment case rested on four factors: the legal priority of first lien term loan claims, the 32-34% discount to par creating immediate value and downside cushion, the near-term catalyst forcing value realization within 12-24 months, and the asset coverage providing 47-64% recovery even in liquidation scenarios. Nothing else mattered nearly as much as these four factors.

Step 4: Business Analysis—Understanding What You Own

Even though the core thesis centered on capital structure positioning and near-term catalyst, I still invested significant time understanding the business in detail. This serves two critical purposes: it helps me assess true downside scenarios by understanding what assets actually exist and whether they have value in a liquidation, and it reveals whether there’s operational upside optionality beyond the base restructuring case.

Mallinckrodt operated through two distinct segments with very different characteristics and competitive dynamics. The Specialty Brands segment represented approximately 76% of net sales (roughly $1,450 million of the $1,919 million total) and encompassed branded pharmaceutical products for autoimmune and rare diseases. This segment included Acthar Gel ($516mm in net sales), the flagship product with FDA approvals for treating over a dozen conditions including infantile spasms and multiple sclerosis exacerbations. The product had demonstrated extraordinary pricing power, with costs increasing from $40 in 2001 to over $34,000 per vial by 2022—an 85,000% increase driven by Mallinckrodt’s monopoly position on this particular molecule that competitors couldn’t exactly duplicate.

INOmax ($340mm in net sales) provided another key component of the Specialty Brands portfolio, representing the only FDA-approved inhaled nitric oxide therapy for hypoxic respiratory failure in neonates. The product benefited from high barriers to entry due to delivery system complexity and established clinical protocols in neonatal intensive care units. Therakos ($240mm) offered extracorporeal photopheresis treatment for cutaneous T-cell lymphoma and chronic graft-versus-host disease. Amitiza ($159mm) was the only branded product with a chloride channel type-two activator mechanism available in three separate constipation indications. These products collectively generated gross margins of approximately 70.9% for the Specialty Brands segment.

The Specialty Generics segment contributed approximately 24% of net sales (roughly $645 million) and focused on complex generic drugs and active pharmaceutical ingredients (APIs). The segment included opioid-based pain management products ($207mm), ADHD medications ($46mm), addiction treatment products ($65mm), controlled substances APIs ($85mm), and acetaminophen APIs ($208mm). Mallinckrodt operated as the exclusive producer of bulk acetaminophen in North America and Europe, and maintained one of the largest controlled substance pharmaceutical businesses in the U.S. The segment generated gross margins of approximately 11.6%, substantially lower than Specialty Brands but with steadier demand patterns and lower research requirements.

The business analysis revealed several critical insights for the downside protection assessment. First, despite the challenges facing Acthar Gel (including competition concerns and pricing scrutiny), the product maintained substantial pricing power due to its complex molecule and monopoly position. Even a 40-50% decline in Acthar revenue would still leave a profitable core business. Second, the Specialty Generics segment had posted seven consecutive quarters of growth through early 2023, demonstrating operational resilience and suggesting this segment could provide stable cash flow even if Specialty Brands faced headwinds. Third, the company’s manufacturing infrastructure included specialized controlled substance production capabilities with significant regulatory barriers to entry through DEA licensing and quota allocations—these barriers created inherent value in the manufacturing assets beyond just the financial performance.

The key observation from this operational analysis: the business as a whole still generated $669 million of EBITDA on $1.9 billion of revenue despite all the challenges. This wasn’t a situation where the company had lost its ability to operate profitably or generate cash. It was purely a balance sheet and liquidity problem caused by excessive leverage and near-term maturities, not an operational death spiral. The business quality provided confidence that asset values in any restructuring or liquidation would support meaningful recovery for secured creditors.

Step 5: Deep Covenant Analysis—Understanding What Protects You

This section deserves extensive attention because covenant analysis is where most investors fail to do the detailed work that actually protects capital in distressed situations. When I analyze debt securities, particularly term loans in leveraged situations, I spend considerable time reading the credit agreement and understanding exactly what rights and protections exist.

The 2017 Replacement Term Loan operated under a credit agreement that provided several key protections to lenders, though as a “cov-lite” structure it lacked the quarterly maintenance financial covenants typical of traditional bank loans. Understanding these provisions required carefully reading the credit agreement and thinking through how each covenant would operate in various restructuring scenarios.

Limitation on Disposals and Asset Sales

The credit agreement included a covenant restricting asset disposals, which was critically important given concerns about potential value stripping. The covenant permitted certain ordinary course disposals but required that proceeds from material asset sales be either reinvested in the business within one year or used to prepay the term loans. This prepayment provision meant that if Mallinckrodt sold valuable assets like the Acthar Gel intellectual property or manufacturing facilities, term loan holders would either benefit from reinvestment that maintained the asset base securing their loans, or receive direct prepayment at par.

The covenant included typical exceptions for intercompany transfers among guarantor entities, disposals of obsolete equipment, and small disposals below specified thresholds. However, any material disposition outside these exceptions would trigger the proceeds sweep. This protection directly addressed the risk highlighted by the Envision Healthcare bankruptcy situation, where concerns about asset stripping to affiliates had impaired creditor recoveries. The Mallinckrodt covenant structure, while not as tight as some credit agreements negotiated post-Envision, still provided meaningful protections against the most egregious forms of value leakage.

Limitation on Distributions and Restricted Payments

The credit agreement restricted Mallinckrodt’s ability to pay dividends, make distributions to equity holders, or otherwise move cash out of the restricted group of obligors. This covenant operated through a combination of fixed dollar baskets permitting specified amounts of distributions, plus a “builder basket” that grew based on cumulative consolidated net income.

Critically, given Mallinckrodt’s negative net income in recent periods, the builder basket was deeply negative, meaning no capacity existed under that provision. The fixed baskets were sized relatively conservatively and couldn’t accommodate material distributions. This meant that cash generated by the operating businesses would remain trapped within the obligor group and available to service the term loan rather than being paid out to equity holders or moved to unrestricted subsidiaries outside the reach of creditors.

Limitation on Liens and Security Package

The liens covenant restricted Mallinckrodt’s ability to grant liens on assets except for specified “Permitted Liens.” These Permitted Liens included typical exceptions for purchase money security interests in equipment, statutory liens for unpaid taxes, and most importantly, liens securing the term loans and pari passu first lien bonds.

The security package itself provided first-priority perfected security interests in substantially all assets of Mallinckrodt International Finance SA and the guarantors. The collateral included all present and after-acquired tangible and intangible assets, specifically including intellectual property (patents related to Acthar Gel, INOmax, Therakos, and other products), equipment and manufacturing facilities, inventory, accounts receivable, and the equity interests of subsidiary entities. The security interests were perfected through UCC financing statements filed in appropriate jurisdictions, with intellectual property security interests separately recorded with the USPTO.

The comprehensiveness of this security package was crucial to the downside protection thesis. Unlike unsecured claims or security interests in only certain specified assets, the first lien covered virtually everything of value in the business. In any restructuring or liquidation, first lien holders would have direct claims on the IP portfolio, manufacturing assets, working capital, and subsidiary equity that formed the core value of Mallinckrodt.

Limitation on Mergers and Fundamental Changes

The credit agreement restricted Mallinckrodt’s ability to engage in mergers, consolidations, or sales of all or substantially all assets except in compliance with specified conditions. These conditions typically required that the surviving entity assume all obligations under the credit agreement, maintain sufficient asset coverage, and preserve the security interests.

This covenant prevented the company from merging into an entity with weaker credit or selling the core business without ensuring that term loan holders would be repaid at par or maintain equivalent security and credit support. It provided protection against reorganization transactions that might attempt to leave term loan holders behind with inferior claims.

Interest Rate and Hedging Provisions

The term loan bore interest at LIBOR (with a 75 basis point floor) plus 525 basis points. With LIBOR in the 4-5% range in early 2023, the all-in interest rate was approximately 9.5-10.0%, creating substantial interest burden but also substantial current income for holders who bought at distressed levels. The credit agreement permitted interest rate hedging, and the original analysis contemplated using interest rate swaps to lock in the LIBOR component and reduce variability in the cash flows.

One important structural feature was the 2.5% annual amortization requirement, meaning the term loan would amortize by approximately $31 million per year ($1,238mm * 2.5%). While this represented modest deleveraging in the context of the overall debt burden, it provided a mechanism for gradual debt reduction even absent prepayments from asset sales or excess cash flow.

Absence of Maintenance Covenants

As a “cov-lite” loan structure, the 2017 Replacement Term Loan lacked the quarterly maintenance financial covenants (such as maximum leverage ratios or minimum interest coverage ratios) that were typical of traditional bank loans. This meant Mallinckrodt could allow its credit metrics to deteriorate significantly without triggering a technical default, as long as the company made required interest and principal payments and complied with the negative covenants described above.

The mitigant for this looser covenant structure was Mallinckrodt’s status as a publicly traded company with quarterly financial reporting obligations. Term loan holders would receive timely financial information through SEC filings even absent covenant compliance certificates, enabling active monitoring of credit deterioration. Additionally, the near-term maturity catalyst meant that covenant flexibility was less relevant—the company would need to refinance or restructure within 12-24 months regardless of covenant compliance, so the focus should be on recovery analysis rather than covenant cushion.

The comprehensive covenant analysis revealed that while the cov-lite structure provided less creditor control than traditional bank loans, the security package, asset sale proceeds application, and restrictions on value leakage provided meaningful protections for a first lien position. The absence of quarterly maintenance covenants increased monitoring requirements but didn’t fundamentally impair the downside protection thesis given the near-term catalyst.

Step 6: Downside Analysis—Where 80% of Analytical Time Goes

This is where I diverge most dramatically from typical Wall Street analysis. While most analysts spend their time building upside cases and target prices, I spend approximately 80% of my analytical time on one question: what can I lose, and what protects me from losing it? This relentless focus on downside is what creates actual edge in distressed credit analysis.

For Mallinckrodt, I began the downside analysis by studying the liquidation analysis that had been prepared during the first bankruptcy proceedings. This analysis provided a starting framework that I then refined and stress-tested based on current circumstances.

Bankruptcy Liquidation Analysis Framework

The bankruptcy liquidation analysis from the first Chapter 11 case provided a hypothetical assessment of proceeds that would be obtained if Mallinckrodt were liquidated under Chapter 7 of the Bankruptcy Code. This analysis applied recovery percentages to each asset category on the balance sheet, ranging from conservative low-end assumptions to more optimistic high-end assumptions.

For cash of $410 million, the analysis assumed 100% recovery in both scenarios since cash is immediately liquid. This seemed reasonable given that this represented unrestricted cash that wouldn’t be consumed by administrative expenses given the substantial asset base.

For accounts receivable of $405 million, the analysis assumed 70-85% recovery. This reflected that while most receivables from major pharmaceutical wholesalers and government payors would be collectible, some portion would be disputed, uncollectible, or subject to offsets. The midpoint recovery of approximately 77.5% produced liquidation value of $314 million from receivables.

For inventory of $948 million (a surprisingly large number that raised questions about balance sheet quality), the analysis assumed only 9-13% recovery. This harsh assumption reflected that pharmaceutical inventory has limited shelf life due to expiration dating, much of it is work-in-process or raw materials with limited value outside the integrated manufacturing process, and breaking up the business would disrupt supply chains making inventory difficult to monetize. The midpoint recovery of 11% produced liquidation value of $104 million—a dramatic haircut suggesting that book value overstated realizable value by nearly 90%.

For property, plant and equipment of $458 million, the analysis assumed 10-30% recovery. Pharmaceutical manufacturing facilities have some real estate value, but the specialized nature of the equipment and the costs of environmental remediation and decommissioning would materially impair realizable values. The midpoint recovery of 20% produced liquidation value of $92 million from PP&E.

For intangible assets of $2,843 million (the largest asset category by far), the analysis assumed only 8-15% recovery. This conservative assumption reflected the difficulty of monetizing intellectual property in liquidation, the limited buyer universe for specialized pharmaceutical patents, and the uncertainty around ongoing royalty streams. The midpoint recovery of 11.5% produced liquidation value of $327 million from intangibles—again, a massive haircut suggesting book value overstated liquidation value by nearly 90%.

Total Liquidation Value and Coverage Analysis

Aggregating across all asset categories, the bankruptcy liquidation analysis produced total proceeds ranging from a low of $1,217 million to a high of $1,673 million, with a midpoint of $1,445 million. Comparing these proceeds to the $2,606 million of pari passu first lien debt (term loans plus first lien bonds), the analysis showed recovery percentages of 47% on the low end, 64% on the high end, and 55% at the midpoint.

This liquidation analysis had profound implications for the investment thesis. Even in a worst-case forced liquidation scenario with punitive assumptions on asset recoveries, the first lien debt would recover approximately 47-64% of par. For an investor buying the 2017 Replacement Term Loan at 66-68% of par, this meant that even in liquidation you would be close to breakeven on a principal basis, while having collected substantial interest payments during the holding period.

Expressed differently, the liquidation analysis suggested that asset values could decline by approximately 35-40% from the already-conservative liquidation assumptions before creating principal losses for investors buying at 66-68% of par. This provided extraordinary downside protection—you had to be dramatically wrong about liquidation recoveries to lose money on the investment.

Going-Concern Valuation and Recovery Analysis

The next layer of downside analysis involved evaluating going-concern enterprise value using multiple methodologies. Unlike liquidation which assumes the business is broken up and sold piecemeal, going-concern valuation assumes the business continues operating as an integrated entity, either through successful restructuring or through sale to a strategic or financial acquirer.

I developed a comparable companies analysis examining Mallinckrodt relative to peer specialty pharmaceutical companies. The analysis included Viatris (trading at 5.62x EV/EBITDA with 3.24x net leverage), Teva Pharmaceuticals (5.74x EV/EBITDA with 5.10x net leverage), and Amneal (5.62x EV/EBITDA with 5.03x net leverage). The peer average EV/EBITDA multiple was approximately 4.92x—nearly double Mallinckrodt’s implied multiple of 2.69x based on the distressed debt trading levels.

Applying peer multiples to Mallinckrodt’s $669 million of EBITDA produced enterprise values ranging from $2,799 million (at the peer average 4.92x multiple) to $3,840 million (at the peer high 5.74x multiple). Even using the low-end peer multiple of 4.24x—which was actually Mallinckrodt’s own distressed trading multiple—produced enterprise value of $2,837 million. All of these valuations provided full coverage for the $2,606 million of first lien debt, with substantial equity value remaining.

I then constructed a recovery waterfall that showed how enterprise value at various multiples would flow through the capital structure. Using 2022 EBITDA of $669 million as the baseline, I created a matrix showing recovery percentages for different combinations of EBITDA performance and valuation multiples.

At the current 2022 EBITDA of $669 million and a distressed 2.69x multiple (far below any peer), first lien debt would recover 69% ($1,800mm EV less $410mm cash equals $2,210mm for debt; $2,210mm / $2,606mm first lien debt = 69% recovery). At the same EBITDA level but the peer average 4.92x multiple, first lien debt would recover 126% ($3,291mm EV less $410mm cash equals $2,881mm; $2,881mm / $2,606mm = 126% recovery). This suggested that even modest multiple expansion to peer levels would provide full par recovery plus equity participation for first lien holders.

The sensitivity analysis revealed that first lien debt achieved 100% recovery at an EV/EBITDA multiple of approximately 3.81x (roughly halfway between the distressed 2.69x trading level and the peer average). This 3.81x multiple still represented a substantial discount to peers, suggesting that the market didn’t need to fully re-rate Mallinckrodt to peer multiples for first lien holders to recover par—just a partial recovery from the deeply distressed levels would suffice.

Stress Testing and Break-Even Analysis

With the base liquidation and going-concern analyses complete, I then stress-tested the assumptions to understand what would need to go wrong for the investment to produce losses. This stress testing framework examined both EBITDA degradation and multiple compression simultaneously.

In Stress Test One, I assumed EBITDA declined 15% from the $669 million baseline to approximately $569 million, reflecting significant operational deterioration from Acthar Gel competition, generic pricing pressure, and execution failures. Even with this reduced EBITDA, applying the distressed 2.69x multiple produced enterprise value of $1,531 million and first lien recovery of 59%. Using a more reasonable 3.81x multiple (still below peers) produced recovery of 83%. The first lien debt maintained value even with substantial operational deterioration.

In Stress Test Two, I assumed EBITDA grew modestly to $719 million (reflecting successful new product launches and Specialty Generics strength offsetting Acthar Gel challenges), but the multiple remained depressed at 2.69x due to persistent market skepticism. This scenario produced enterprise value of $1,934 million and first lien recovery of 74%—better than the base liquidation case despite using distressed multiples.

The most severe stress scenario combined EBITDA decline to $569 million with the rock-bottom 2.69x multiple, producing first lien recovery of 59%. For an investor buying at 66-68% of par, even this catastrophic scenario would generate modest losses of 7-9 cents on the dollar, partially offset by interest income collected during the holding period. Conversely, any scenario where EBITDA remained around current levels and multiples recovered even modestly toward peers would generate full par recovery or better.

The break-even analysis revealed that purchasing the term loan at 66-68% of par created a massive margin of safety. The investment would break even on a total return basis (accounting for interest income) even if enterprise value in a restructuring/sale was only $1,900-2,000 million—representing just 2.8-3.0x EBITDA. Given that liquidation analysis suggested $1,445 million of asset value and going-concern analysis suggested $2,800-3,800 million of enterprise value, the downside cushion was extraordinary.

Step 7: Scenario Analysis and Returns—The Upside is Known

After spending 80% of analytical time on downside protection, scenario analysis becomes straightforward because the upside in distressed credit investing is largely known and bounded. Unlike equity investing where upside is theoretically unlimited, secured debt instruments have defined payoff profiles that cap returns at par plus accrued interest, with potential additional upside from negotiated premiums in restructuring contexts.

Base Case Scenario: Restructuring with Pull to Par

The base case scenario assumed Mallinckrodt would consummate a restructuring or refinancing driven by the upcoming April 2025 maturities and the June 2023 opioid payment deadline. In this scenario, the company would engage in either an out-of-court exchange offer or a prepackaged Chapter 11 bankruptcy that would extend maturities, potentially convert some debt to equity, and establish a sustainable capital structure.

As a first lien term loan holder, the base case assumed you would receive par recovery on your claims. This reflected the strong asset coverage demonstrated in the downside analysis, the legal priority of first lien claims, and the natural outcome in most restructurings where the most senior secured creditors are paid in full or close to full to avoid complex cramdown fights. Management had indicated openness to asset sales and strategic alternatives to deleverage, supporting the view that value preservation was a priority.

The return calculation for this scenario began with the 66-68% purchase price. Taking the midpoint of 67% as the cost basis, I projected holding the term loan through the restructuring catalyst in mid-2024 (approximately 12-15 months holding period from the May 2023 analysis date). During this period, the term loan would generate interest income at LIBOR+525bps, which at prevailing rates translated to approximately 10% annual coupon, producing roughly $10-15 in income per $100 of par value.

At the restructuring, receiving par recovery meant proceeds of $100 per $67 investment. Combined with the interest income, total cash return would be approximately $110-115 per $67 invested over 12-15 months. This produced an internal rate of return of approximately 27.6% and a multiple on invested capital of 2.10x. These were outstanding returns for a secured credit instrument with substantial downside protection.

Importantly, the base case didn’t require exceptional operational performance. EBITDA could decline modestly from current levels, Acthar Gel could face continued pressure, and the market could remain skeptical—none of that would prevent full par recovery for first lien holders given the asset coverage. The returns came from exploiting the distressed purchase price and the near-term catalyst, not from operational improvements or multiple expansion.

Upside Case: Enhanced Recovery in Restructuring

The upside scenario contemplated a restructuring where first lien lenders received par plus additional consideration, either through equity participation, higher coupon rates on extended debt, or negotiated premiums for agreeing to provide new money or extend maturities. This scenario reflected the strong bargaining position of first lien holders who controlled the most senior claims in the capital structure.

Specific mechanisms for enhanced recovery could include: receiving par plus 10-15% in equity warrants if second lien debt was converted to equity, negotiating a premium to par (102-105%) in exchange for providing new capital or agreeing to term extensions, or receiving higher coupon rates on restructured debt that could be sold at premiums shortly after restructuring. Bloomberg Law had reported that lenders were pitching proposals that included bidding for assets through another bankruptcy, suggesting aggressive postures from the creditor group that could result in enhanced recoveries.

The return calculation in the upside scenario assumed par plus 10% equity participation or equivalent value, producing proceeds of $110 per $67 invested plus interest income. This generated an IRR approaching 35% and MOIC of 2.3x. The upside scenario wasn’t necessary for the investment to be attractive, but it represented plausible additional value from the strong negotiating leverage of the first lien position.

Downside Case 1: Restructuring with Haircut

The first downside scenario assumed a restructuring where operational performance deteriorated more than expected, requiring first lien lenders to accept a haircut to facilitate a viable reorganization. This scenario contemplated a negotiated exchange where term loan holders received 60% of par in cash plus equity consideration in the reorganized entity.

The return calculation assumed receiving $60 in cash per $100 of par value, plus equity valued at approximately $15-20 per $100 of par based on the residual enterprise value after satisfying the reduced debt claims. Combined with interest income during the holding period, total proceeds would be approximately $85-90 per $67 invested over 12-18 months. This produced an IRR of approximately 16.7% and MOIC of 1.55x.

Even in this downside scenario, the investment generated attractive returns due to the deep discount to par at purchase. The scenario was conservative in assuming a significant haircut for first lien lenders despite the strong asset coverage, but even with that conservative assumption the risk-adjusted returns remained compelling.

Downside Case 2: Liquidation

The most conservative scenario assumed full liquidation of the company under Chapter 7, with assets sold piecemeal and proceeds distributed according to the bankruptcy priority waterfall. This scenario used the midpoint liquidation values from the bankruptcy analysis: $1,445 million in total liquidation proceeds.

The recovery waterfall showed that after administrative expenses and priority claims (estimated at $64 million based on the bankruptcy analysis), approximately $1,381 million would be available for first lien secured claims totaling $2,606 million. This produced a pro rata recovery of 53% for first lien holders.

The return calculation assumed receiving 53% recovery ($53 per $100 of par, or $53 per $67 invested) plus interest income during an extended workout period of 18-24 months. Total proceeds of approximately $65-70 per $67 invested produced an IRR of approximately 12.3% and MOIC of 1.37x.

This liquidation scenario, while producing the lowest returns, still generated positive returns due to the deep discount to par at purchase and the interest income during the workout period. The scenario represented a true worst case where going-concern value was completely destroyed and assets could only be monetized in forced liquidation—a low probability outcome given that strategic acquirers would likely pay going-concern premiums to acquire the integrated business.

Probability-Weighted Expected Returns

Assigning probabilities to each scenario based on the comprehensive analysis, I weighted the base case at 60% probability given the strong asset coverage, management’s stated willingness to pursue strategic alternatives, and the near-term catalyst that would force resolution. The upside case received 15% probability, reflecting the possibility but not certainty that lenders could extract enhanced terms given their strong position. The restructuring with haircut scenario received 15% probability as a conservative middle case. The liquidation scenario received 10% probability, reflecting the low likelihood of complete value destruction given the business fundamentals and strategic value to potential acquirers.

The probability-weighted analysis produced expected IRR of approximately 23% and expected MOIC of 1.85x. These expected returns were exceptional for a secured credit investment with the downside protection demonstrated in the liquidation analysis.

Why This Return Profile Was Compelling

The return analysis revealed the core attractiveness of the investment opportunity. The expected 23% IRR with strong downside protection compared extraordinarily favorably to returns available elsewhere in the distressed debt market in mid-2023. High yield bonds of comparable credit quality typically yielded 8-10%, senior secured loans in performing credits yielded 10-12%, and mezzanine debt yielded 12-15%. Distressed debt opportunities in other situations might offer similar returns but often with less tangible asset backing and less clear catalysts.

The asymmetry was the key feature that made this compelling. In the upside and base cases (representing 75% combined probability), you generated returns of 20-35% with full or near-full principal recovery. In the downside cases (representing 25% combined probability), you still generated positive returns of 12-17% due to the discount to par and interest income. The worst case scenario of principal loss was extremely remote given the asset coverage, and even that scenario would generate only modest losses offset partially by interest income.

This type of asymmetric payoff—strong returns in most scenarios, positive returns even in bad scenarios, and minimal risk of significant principal loss—is exactly what creates edge in distressed credit investing.

Comparing Across the Capital Structure

The scenario analysis gained additional power by comparing the first lien term loan to alternative investments in the same capital structure. This relative value analysis ensured capital was allocated to the most attractive point in the structure.

The first lien bonds (trading at 75-81% of par) offered similar structural protections to the term loan with pari passu security interests. However, the bonds traded at tighter levels relative to par than the term loans, offering less upside to par recovery while having identical downside protection. The term loan at 66-68% offered better risk-adjusted returns than the bonds at 75-81% despite identical legal positioning.

The second lien bonds (trading at 48-58% of par) appeared superficially attractive given the steep discount. However, the scenario analysis revealed material differences in recovery profiles. In the base case restructuring, second lien would likely receive equity consideration rather than full cash recovery, with uncertain valuation. In liquidation scenarios with $1,445mm of proceeds, second lien holders would receive zero recovery after first lien claims consumed $2,606mm of the proceeds. The second lien bonds faced genuine principal impairment risk in any scenario where enterprise value didn’t recover toward peer multiples—risk that wasn’t adequately compensated by the modestly steeper discount relative to the first lien term loan.

The equity represented the highest risk, highest potential return position. In scenarios where operational turnaround succeeded and multiples re-rated toward peers, equity could multiply several times from the distressed $56 million market cap. However, equity required every factor to go right simultaneously—Acthar Gel stabilizing, new products succeeding, costs declining, and the market rewarding the story with multiple expansion. In any restructuring scenario, existing equity faced severe dilution or wipeout as debt was converted to new equity. The binary nature of the equity bet made it dramatically less attractive on a risk-adjusted basis than the first lien term loan where you got paid well even when things went modestly wrong.

Step 8: The Investment Memo Structure

After completing all the analytical work, I synthesized the findings into a formal investment memorandum that documented the thesis, analysis, and recommendation. Understanding this structure helps clarify how to organize thinking about any investment opportunity. Let me share the exact structure and what goes in each section:

1. Executive Summary & Recommendation

What is your overall recommendation with respect to a debt or equity investment in the company and why? Focus on the core of the transaction and key investment highlights.

Relevant questions to address include: (i) what is the transaction including pro forma capital structure, (ii) what does the company do, (iii) what is the purpose of the debt, and (iv) what are the top investment highlights, risks, and why? Please be sure to include IRR, MOIC, and P&L statistics as part of your Executive Summary & Recommendation.

For Mallinckrodt, the Executive Summary articulated: “Based on the analysis conducted, I recommend investing in Mallinckrodt Plc by purchasing the 2017 Replacement Term loan at 66-68% of par. The company is a global pharmaceutical company with robust business fundamentals generating approximately $2 billion in net sales and $669 million in EBITDA (35% margin) despite facing litigation uncertainties and operational challenges. The upcoming 2025 debt maturities combined with the June 2023 opioid payment creates a near-term catalyst that will force restructuring within 12-24 months. The term loan offers substantial margin of safety with first lien security on all assets and decent option value on the upside. Analysis of three scenarios—Base Case, Restructuring, and Liquidation—reveals attractive investment returns: Base Case IRR of 28% and MOIC of 2.1x; Restructuring IRR of 16.7% and MOIC of 1.55x; and even in Liquidation scenario, IRR of 12.3% and MOIC of 1.37x.”

2. Key Terms of Purchase

Should be a short form description of the instrument covering key items: equity, share price, loan or bond amount, tenor/maturity, interest rate, other fees/economics, call protection, amortization, security/priority/collateral, covenants, and other structural features. Please add any covenants/structural nuances in clean, concise fashion.

This section documented that the 2017 Replacement Term Loan was issued by Mallinckrodt International Finance SA, had global size of $1,238 million, matured in September 2027, bore interest at LIBOR (floored at 75bps) + 525bps, required 2.5% annual amortization, and featured first lien security equal and ratable with liens securing the First Lien Bonds on substantially all assets of the issuers and guarantors. Key covenants included limitations on disposals, distributions, dividends, liens, and mergers. Upon asset sales, proceeds must be reinvested within one year or used to prepay the term loan.

3. Business Summary

Brief overview of the company (description of the business and summary analyses, e.g., segment contribution, margin analysis, product revenues etc.).

This section described the two business segments, the key products within each segment (Acthar Gel at $516mm, INOmax at $340mm, Therakos at $240mm in Specialty Brands; opioids, ADHD meds, controlled substance APIs in Specialty Generics), the manufacturing and commercial infrastructure, and financial performance showing gross margins of 32% overall (70.9% for Specialty Brands, 11.6% for Specialty Generics), with historical challenges around legal issues, pricing pressures, and the allegations of financial fraud by Buxton Helmsley raising concerns about balance sheet quality.

4. Investment Highlights

Outline what you like about the investment and why.

The highlights included: (1) Significant enterprise value at current trading levels and near-term crystallization event provides opportunity to offer better terms for optionality—the 2025 refinancing serves as a short-term catalyst, with potential for enhanced recovery if debt is restructured with lender participation; (2) Intellectual property portfolio includes assets with little or no competition, including Acthar IP with monopoly positioning and pricing power demonstrated by the 85,000% price increase since 2001; (3) Strengthened credit after favorable ruling allowed Mallinckrodt to monetize Acthar Gel IP without making agreed-upon royalty payments to Sanofi-aventis, effectively adding value that flows to secured creditors rather than unsecured royalty holders.

5. Key Risks and Mitigants

Outline what you see as key risks and potential mitigants you have identified.

Five major risks were identified with specific mitigants: (1) Risk: Lack of investor interest may hinder ability to refinance 2025 debt; Mitigant: Management proactively considering asset sales and multiple options to deleverage. (2) Risk: Heightened risk of IP/asset stripping given “loose” loan documents post-GFC; Mitigant: Loan agreement includes specific provisions restricting disposals, transfers with affiliates, and liens, plus conducting comprehensive legal due diligence comparing to Envision credit agreement. (3) Risk: Cov-lite structure with no maintenance covenants increases exposure to credit risk; Mitigant: Quarterly SEC reporting provides sufficient financial disclosure for active monitoring. (4) Risk: Sales heavily rely on Acthar Gel and INOmax, with affordable alternatives posing pricing threat; Mitigant: Projections account for 10-15% negative impact from new Acthar competitor, partially offset by return to pre-pandemic prescriber behavior, clinical trial data, and self-injector device launch. (5) Risk: High interest payments and opioid settlement payments may cause liquidity concerns; Mitigant: $410 million cash provides short-term coverage, and potential Chapter 22 bankruptcy would see bank debt paid as senior secured while opioid payment ranks as unsecured claim pari passu with second lien.

6. Returns & Scenario Analysis

Summarize your modeling/analysis from the corporate model. Outline the key performance indicators to the transaction (IRR, MOIC, P&L). Include your assumptions and rationale for each scenario you deem relevant to the analysis of the company. In all cases, the scenarios should include outputs that show the impact to various covenants and explain why.

This section presented three scenarios based on crystallization events around the 2025 maturity: Base Case (company meets all financial obligations, generates 27.6% IRR and 2.10x MOIC), Restructuring (cannot refinance 2025 maturities, cash/debt exchange at 60% of par with second lien converted to equity, generates 16.7% IRR and 1.55x MOIC), and Liquidation (full liquidation using midpoint values from liquidation analysis, generates 12.3% IRR and 1.37x MOIC). All scenarios used management’s financial projections without adjustments, with cost basis of 66% of par creating $19.8mm investment in $30mm par amount.

7. Collateral / Liquidation / Downside Analysis

Outline the nature of any security/collateral in the transaction, your rational and view on its value (e.g., any asset value or a broader view on total enterprise value of the company), and your analysis of what proceeds may be generated in a liquidation and subsequent flow through a waterfall analysis.

This section presented the bankruptcy liquidation analysis showing total proceeds of $1,217mm (low), $1,673mm (high), and $1,445mm (midpoint), producing first lien debt coverage of 47%, 64%, and 55% respectively. The analysis detailed recovery assumptions for each asset category: cash 100%, A/R 70-85%, inventory 9-13%, PP&E 10-30%, intangibles 8-15%. Additionally presented comparable companies analysis showing peer multiples of 4.92-5.74x EV/EBITDA versus Mallinckrodt’s distressed 4.24x, with recovery tables showing that at current $669mm EBITDA and 2.69x multiple first lien recovers 69%, while at peer average 4.92x multiple first lien recovers 126%. Even at EV/EBITDA multiples half of closest comparable company, recovery ranges from 69-132% based on EBITDA scenarios.

8. Business Analysis

Outline your understanding of the sector, the company compared to others. Include financial analysis (three statement analysis, transaction/valuation multiples, capital structure analysis, and any other supplemental analysis you deem relevant) and include review of historical performance to the extent possible.

This comprehensive section detailed the Specialty Brands segment’s competitive positioning in autoimmune and rare diseases, with detailed product analysis of Acthar Gel’s differentiation through ongoing studies and self-injection device development, INOmax’s competitive position through service differentiation and next-generation delivery system, and Amitiza’s unique position as the only branded product with specific mechanism across three constipation indications. The Specialty Generics section described the controlled substances focus, exclusive North American and European acetaminophen production, and competitive positioning against Rhodes, Teva, Aurobindo, and Amneal through secure opioid raw material sources, vertical integration, and established distributor relationships. Historical financial analysis showed net sales declining from $3.2 billion (2018) to $1.9 billion (2022), but EBITDA margins remaining resilient at 35-40% range, with the business generating $703 million of levered free cash flow in 2022 despite the challenges.

The Investment Philosophy in Action

Returning to my four core principles, the Mallinckrodt analysis demonstrates how rigorous process creates clarity and conviction in distressed credit situations.

Principle 1: Focus on Process-Oriented Risks

The traditional analyst approaching Mallinckrodt would have built elaborate models projecting Acthar Gel market share evolution based on regression analysis of prescription trends, detailed competitive response scenarios from potential generic entrants, and margin bridge analyses showing how cost reductions would flow through to EBITDA over five years. None of this mattered for the first lien term loan investment thesis.

What mattered were process-oriented factors: what were the asset liquidation values based on the bankruptcy court analysis, was the security package properly perfected with first-priority liens on all valuable assets, what were the mechanics of the 2025 maturity wall and how would it force a crystallization event, and most importantly, what would the recovery waterfall look like in various restructuring or liquidation scenarios? These structural and legal questions determined outcomes, not operational projections that were inherently uncertain given the company’s history of missing forecasts.

By focusing on process rather than operations, I could reach high conviction on the investment despite substantial uncertainty around the operational outlook. I didn’t need to know whether Acthar Gel would decline 10% or 25% annually. I didn’t need to know whether the self-injector device would be successful or whether Specialty Generics could maintain growth. I just needed to know that asset values of $1,445 million in conservative liquidation provided 55% recovery for first lien debt, and that any going-concern restructuring would almost certainly provide full par recovery given the business continued to generate $669 million of EBITDA.

Principle 2: Focus Only on Downside

The Mallinckrodt analysis embodied this principle through both time allocation and analytical depth. I spent weeks building the liquidation analysis asset-by-asset, studying the bankruptcy court liquidation analysis, stress-testing recovery assumptions, and calculating break-even enterprise values under various scenarios. The upside analysis—what if operational performance improves and multiples re-rate—took hours, not weeks, because the upside was largely bounded at par recovery plus potential modest premiums or equity participation.

This focus on downside created the analytical edge that most investors missed. Market participants in mid-2023 were debating whether Acthar Gel could stabilize, whether the Buxton Helmsley fraud allegations had merit, whether management could execute on cost reductions, and whether the company could refinance the 2025 maturities at reasonable terms. These were interesting questions but fundamentally irrelevant to evaluating the downside protection at 66-68% of par.

The investors who focused on these operational and refinancing questions either passed on the opportunity (worried about execution risk) or bought second lien bonds (attracted by the steeper discount without doing the work on recovery analysis). They missed the core insight that a first lien term loan purchased at a 32-34% discount to par with $1,445 million of liquidation value supporting $2,606 million of first lien debt offered extraordinary downside protection that made the operational and refinancing questions secondary considerations.

Principle 3: Always Ask “What Am I Missing?”

Throughout the analysis, I systematically challenged my own assumptions by working through structured questions that forced me to consider what could go wrong with the thesis. What if the liquidation analysis overstated asset values? I tested this by applying even harsher recovery percentages—reducing intangible asset recovery from 11.5% to 5%, reducing inventory recovery from 11% to 5%—and found that first lien recovery only declined from 55% to approximately 43%, still providing reasonable protection at the 66-68% purchase price.

What if the fraud allegations by Buxton Helmsley indicated massive hidden liabilities or asset value destruction? I researched the specific allegations, attempted to contact Buxton Helmsley for details, and concluded that while the allegations raised questions about balance sheet quality (particularly the inflated intangible asset values that were subsequently written down), they actually supported the conservative liquidation analysis which already assumed 89% haircuts on intangibles. The fraud allegations didn’t create new downside risk—they validated the conservative asset assumptions.

What if strategic buyers wouldn’t pay going-concern premiums and the only path was liquidation? Even in this scenario, the liquidation analysis showed 47-64% recovery, and with interest income during an 18-24 month workout period, total returns would still be 12-15% from the 66-68% purchase price. The worst case remained acceptable.

What if lenders couldn’t agree on restructuring terms and the company burned through its cash in a protracted fight? This was a more legitimate concern, but the $410 million cash balance provided runway, the business generated positive free cash flow, and most importantly, all first lien lenders (term loans and bonds) had aligned interests in maximizing recovery, reducing the likelihood of intractable disputes.

The systematic interrogation of assumptions through “what am I missing?” questions didn’t uncover any scenario that broke the investment thesis. Every question had a satisfactory answer grounded in asset coverage, legal priority, or the mechanics of the near-term catalyst.

Principle 4: Everything Boils Down to a Few Factors

After producing a 19-page investment memorandum with detailed business analysis, covenant review, liquidation valuations, comparable company analysis, and scenario modeling, the entire investment thesis distilled to four factors.

First, you could buy first lien secured term loans at 66-68% of par, creating a 32-34% discount that provided immediate margin of safety. This discount was essential—it meant that even in scenarios where first lien debt took haircuts, you could still generate positive returns.

Second, the expected restructuring driven by the 2025 maturity wall would almost certainly eliminate or convert the $590 million of junior second lien debt to equity, dramatically improving the asset coverage ratio for first lien claims. With $1,445 million of conservative liquidation value supporting $2,606 million of first lien debt (55% recovery), eliminating the second lien debt from the liability structure would improve the coverage dynamics and ensure first lien holders captured the going-concern value premium. The market was pricing in significant junior debt recovery, but the reality was that any restructuring would wipe out or severely dilute junior claims, with all going-concern value above liquidation flowing to senior secured creditors.

Third, the term loans had first-priority security interests on substantially all assets including $516 million of Acthar Gel cash flows, $340 million of INOmax cash flows, manufacturing facilities with controlled substance capabilities, and intellectual property with monopoly positioning. The bankruptcy liquidation analysis valued these assets conservatively at $1,445 million, providing the 55% liquidation floor while the going-concern value of $2,800-3,800 million (based on peer multiples) would flow entirely to first lien holders once junior debt was eliminated in restructuring.

Fourth, the upcoming April 2025 maturity wall ($741 million of bonds maturing) combined with the June 2023 opioid payment ($200 million due) would force a crystallization event within 12-24 months. This near-term catalyst meant you wouldn’t wait years for value realization—the maturity wall would force either refinancing, restructuring, or sale within a defined timeframe, and in any of these scenarios, the elimination of junior liabilities would be the mechanism that created value for first lien holders.

These four factors drove the outcome. The investment thesis wasn’t about operational improvements or Acthar Gel stabilization—it was about buying senior secured claims at a discount knowing that the near-term catalyst would force a restructuring that eliminated junior liabilities, allowing first lien holders to capture the full going-concern value premium above the liquidation floor.

What Made This Trade Work

The Mallinckrodt opportunity existed in May 2023 because of multiple forms of market inefficiency that created the distressed pricing. Understanding why opportunities exist is as important as understanding why they’re attractive.

Market Dislocation from Bankruptcy Stigma and Recent Emergence

The company had only emerged from its first bankruptcy in June 2022—less than one year before this analysis. Many institutional investors had policies prohibiting investment in companies that had recently been through bankruptcy, either due to formal mandates or informal guidelines about reputation risk. Additionally, the market memory of the first bankruptcy created skepticism about whether management could successfully execute on the reorganization plan, particularly given the subsequent allegations of financial fraud.

This recent bankruptcy history created mechanical selling pressure and reduced the investor base willing to consider the securities. Traditional bank loan funds that might normally buy first lien term loans in crossover credit situations were prohibited or reluctant. High yield funds that might buy secured bonds were concerned about the distressed credit rating. Distressed debt funds that would naturally be buyers were already full from the first bankruptcy and might not have additional capital to deploy in the same name.

This reduced investor base created the opportunity for investors who could look past the stigma to the structural protections and asset backing.

Complexity Discount from Multiple Uncertainties

The Mallinckrodt situation in May 2023 presented multiple layers of complexity that deterred investors who wanted simpler stories. The allegations of fraud by Buxton Helmsley created uncertainty about balance sheet quality. The upcoming maturity wall created uncertainty about refinancing path. The opioid settlement payments created uncertainty about liquidity. The competitive pressure on Acthar Gel created uncertainty about revenue trajectory. The cov-lite loan structure created uncertainty about creditor control.

Each of these uncertainties was addressable through rigorous analysis—the fraud allegations actually validated conservative asset assumptions, the maturity wall created the catalyst, the opioid payments were sized relative to available liquidity, the Acthar pressure was reflected in projections, and the cov-lite structure was offset by quarterly SEC reporting. But most investors didn’t want to do the work to address five different sources of uncertainty simultaneously. They preferred situations with cleaner stories and fewer moving parts.

This complexity discount created opportunity for investors willing to do detailed work across legal (bankruptcy analysis, covenant review), financial (liquidation valuations, scenario modeling), and operational (business analysis, competitive positioning) dimensions.

Focus on Headlines Rather Than Capital Structure Position

The financial media coverage of Mallinckrodt in early 2023 focused on negative headlines: allegations of fraud, opioid settlement payments, competitive pressure on flagship products, and looming maturity wall. Bloomberg Law’s article on the lender proposals mentioned potential bankruptcy, and Buxton Helmsley’s public letters accused management of deliberately misleading investors about asset values.

These headlines created sentiment that deterred investors who relied on headline risk assessment rather than detailed capital structure analysis. The headlines suggested a troubled company in distress, which many investors equated with investment risk without distinguishing between equity risk (which was substantial) and senior secured debt risk (which was much lower given the asset backing).

By focusing on headlines rather than conducting granular analysis of the capital structure position, collateral values, and recovery dynamics, most market participants missed that the first lien term loan at 66-68% of par offered extraordinary risk-adjusted returns despite—or more accurately, because of—the headline risk.

Time Horizon Mismatch

The 2017 Replacement Term Loan matured in September 2027, over four years away from the May 2023 analysis date. Many institutional investors operated with shorter time horizons driven by quarterly performance measurement, annual bonus cycles, or fund redemption concerns. Even though the investment thesis centered on a 12-24 month catalyst from the 2025 maturity wall, the September 2027 final maturity created perceived illiquidity risk.

Additionally, the distressed nature of the situation created timing uncertainty around exactly when and how the crystallization event would occur. Would it be an out-of-court exchange in Q4 2023? A prepackaged bankruptcy in Q1 2024? A traditional Chapter 11 in Q2 2024? This timing uncertainty made the opportunity unattractive to investors who needed precise catalyst timing for portfolio construction or performance attribution purposes.

This time horizon mismatch created opportunity for patient capital willing to hold through workout uncertainty and accept some timing variability in exchange for the strong risk-adjusted returns and near-term catalyst.

Common Mistakes to Avoid in Capital Structure Analysis

The Mallinckrodt case study illustrates several pitfalls that commonly trap investors in distressed credit situations.

Mistake 1: Over-Modeling Operational Scenarios Without Anchoring to Asset Values

The most common mistake I see in distressed credit analysis is analysts spending weeks building elaborate financial models with detailed product-by-product revenue projections, complex margin bridges showing how cost reduction initiatives flow through to EBITDA, and intricate working capital schedules modeling DSO and DPO evolution. For a secured debt position where the investment thesis rests on asset backing and near-term catalyst, this operational modeling is largely wasted effort.

The alternative approach is spending that time on collateral analysis (asset-by-asset liquidation valuations), bankruptcy process understanding (studying the prior case documents, understanding creditor dynamics), and covenant review (reading the credit agreement to understand exactly what protections exist). These factors determine recovery in downside scenarios, which is all that matters for credit decisions. Knowing whether Acthar Gel revenue will be $450mm or $550mm in 2025 doesn’t help you understand whether the term loan will recover par in a restructuring or what you’ll get in liquidation.

Mistake 2: Ignoring Bankruptcy Court Documents and Prior Case History

Mallinckrodt’s first bankruptcy produced hundreds of pages of court filings including detailed liquidation analyses, asset valuations, creditor recoveries, and legal precedents around the asset purchase agreement with Sanofi-aventis. These documents provided an invaluable roadmap for understanding asset values, typical recovery percentages for different asset categories in pharmaceutical bankruptcies, and how bankruptcy courts analyzed the business.

Most investors ignored these documents or only skimmed the key filings. They relied instead on management presentations and sell-side research that provided high-level overviews without the granular detail. By not reading the bankruptcy court documents in detail, they missed critical information about asset valuations (the liquidation analysis showing 8-15% recovery on intangibles and 9-13% on inventory), about legal positions (the Sanofi-aventis ruling that eliminated future royalty obligations), and about creditor behavior (how different creditor groups negotiated in the first bankruptcy).

The investors who read 200+ pages of bankruptcy court filings gained analytical edge over those who relied on summaries.

Mistake 3: Treating All First Lien Debt as Equivalent Without Analyzing Relative Value

The first lien capital structure included term loans trading at 66-68% and bonds trading at 75-81%. Both had pari passu security interests and identical legal priority. Yet most investors didn’t rigorously compare the two positions to determine which offered better relative value.

The term loans at 66-68% offered 9-13 points of additional upside to par compared to the bonds at 75-81%, while having identical downside protection. This wasn’t a situation where the term loans had materially different covenants or maturity dates that justified the price differential—they were structurally nearly identical. The price difference reflected different holder bases (bank loan funds versus high yield funds) and liquidity preferences rather than fundamental differences in recovery prospects.

By not conducting rigorous relative value analysis within the first lien cohort, investors who bought the bonds at 75-81% gave up 9-13 points of potential return versus buying the term loans at 66-68%, despite taking identical risk.

Mistake 4: Over-Weighting Recent Financial Performance Without Understanding Sustainability

Mallinckrodt’s 2022 financial performance showed meaningful deterioration from prior years, with revenue declining from $2.2 billion to $1.9 billion and gross margins compressing. Some investors extrapolated these trends and assumed continued deterioration would persist, leading them to pass on the opportunity or demand even more distressed entry points.

However, deeper analysis revealed that much of the 2022 deterioration was non-recurring: pandemic-related prescribing pattern disruptions, one-time charges related to bankruptcy emergence, and the initial phase of generic competition. Management’s projections (which I used without adjustment in the scenario analysis) actually showed stabilization in 2023-2024 revenue around $1.8-1.9 billion with modest EBITDA margin improvement.

The correct framework wasn’t projecting linear continuation of recent trends, but rather understanding sustainable cash flow generation capacity. Even applying harsh assumptions (revenue declining another 10-15%, margins compressing 200-300 basis points), the business still generated $500-550 million of EBITDA—enough to support meaningful going-concern enterprise value above liquidation levels. By over-weighting the most recent quarterly results without understanding the factors driving those results, some investors made overly conservative projections that led them to undervalue the recovery prospects.

Conclusion: Simplicity Through Rigor

The paradox of sophisticated investing that this case study illustrates is that the more rigorous your analysis, the simpler your thesis becomes. After more than 40 hours of work analyzing Mallinckrodt across every dimension—reading bankruptcy court documents, building liquidation analyses, modeling scenarios, reviewing covenants, studying competitive dynamics—the entire investment case distilled to one paragraph.

Buy the 2017 Replacement Term Loan at 66-68% of par, creating a 32-34% discount to ultimate recovery value. The upcoming April 2025 maturity wall combined with the June 2023 opioid payment forces a crystallization event within 12-24 months where the $590 million of junior second lien debt will be eliminated or converted to equity, dramatically improving asset coverage for first lien holders. With conservative liquidation value of $1,445 million providing a 55% floor recovery and going-concern value of $2,800-3,800 million (based on peer multiples) that will flow entirely to first lien claims once junior liabilities are eliminated, the risk-reward is extraordinarily asymmetric. Expected returns of 23-28% IRR with minimal principal risk across virtually any realistic scenario.

Nothing else mattered to the investment decision. The operational trajectory of Acthar Gel didn’t matter—asset values provided the floor while junior debt elimination provided the upside. The resolution of the fraud allegations didn’t matter—the liquidation analysis already assumed massive haircuts on intangible assets. The specific structure of any refinancing didn’t matter—first lien priority combined with junior debt elimination ensured full par recovery or better. All of these operational and structural details were completely secondary to the core insight: you were buying senior secured claims at a 32-34% discount knowing that a near-term catalyst would eliminate the junior liabilities sitting between you and the going-concern enterprise value.

This is the power of bottom-up, process-oriented analysis combined with obsessive focus on downside protection. You do weeks of rigorous work to get to a thesis you can explain in sixty seconds. You read hundreds of pages of documents and build multiple valuation frameworks not to create complexity but to eliminate it, stripping away everything that doesn’t matter until you’re left with the two to four factors that determine outcomes. And when you find situations where those factors are verifiable, protective, and mispriced, you have conviction to size positions appropriately and hold through volatility.

The Mallinckrodt case study demonstrates that the best distressed credit investments often hide in situations that appear complicated on the surface but are actually quite simple once you do the work. A pharmaceutical company just out of its first bankruptcy, facing fraud allegations, with a controversial flagship product, competitive pressure, and a looming maturity wall sounds like a nightmare situation that sophisticated investors should avoid. But when you strip away the noise and focus on what matters—legal priority, asset coverage, junior debt elimination catalyst, discount to par—you find an opportunity where you get paid 25%+ annually with strong downside protection.

That’s what I look for: situations where rigorous analysis reveals that you can buy $1.00 of senior secured claims at $0.66 with $0.55 of liquidation value protecting your downside, while a near-term catalyst will eliminate the $0.59 of junior debt sitting between you and the $2.80-3.80 of going-concern enterprise value. The business can underperform, competition can intensify, management can struggle—none of it matters when you have first lien priority and the restructuring catalyst will eliminate junior claims, allowing you to capture the full going-concern premium.

The framework is replicable. Build the model, map the structure, identify the few factors that matter, spend 80% of your time on downside, constantly ask what you’re missing, and find situations where capital structure dynamics create asymmetric opportunities. In this case, the asymmetry came from buying at 66-68% of par with 55% liquidation protection, knowing that restructuring would eliminate junior debt and allow first lien holders to capture enterprise value of $2,800-3,800 million supporting only $2,606 million of claims. That’s the essence of distressed credit investing done right.

---

This does not constitute investment advice or a recommendation to buy or sell any security. Securities investing involves risk of loss. Always conduct your own due diligence and consult with qualified financial, legal, and tax advisors before making any investment decisions.